copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . . In addition, bempedoic acid and statin combination therapy can be used for patients sensitive to high statin doses 6 Diagram of how bempedoic acid inhibits cholesterol synthesis within the liver Adapted from Rusisca et al
Bempedoic Acid: A New Tool for LDL-Cholesterol Control in . . . Abstract Nowdays a small proportion of patients with high very high extreme atherosclerotic cardiovascular disease risk achieves the optimal target of LDL-cholesterol, because of drug intolerance, poor adherence to the therapy, or inapplicability of the stepwise strategy in lipid lowering therapy, recommended by the current guidelines The new oral agent bempedoic acid lowers plasma LDL
Comparative Cardiovascular Benefits of Bempedoic Acid and . . . Background In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events
Effect of Bempedoic Acid vs Placebo Added to Maximally . . . Key Points Question To what extent does bempedoic acid lower low-density lipoprotein cholesterol (LDL-C) levels in patients at high cardiovascular risk who have ongoing hypercholesterolemia, despite the use of maximally tolerated lipid-lowering therapy? Findings In this clinical trial that included 779 randomized patients, the addition to stable background lipid-lowering therapy of bempedoic
Bempedoic acid in the management of lipid disorders and . . . Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i e , the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy
(PDF) Bempedoic Acid: A Novel Approach in Managing . . . This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with
Bempedoic Acid - StatPearls - NCBI Bookshelf Bempedoic acid is a lipid-lowering agent pivotal in managing patients with elevated low-density lipoprotein cholesterol (LDL-C) levels The U S Food and Drug Administration (FDA) has sanctioned its use as an adjunct to maximally tolerated statin therapy for the reduction of LDL-C, specifically in individuals afflicted by atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial
Comprehensive review of statin-intolerance and the practical . . . Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17–28 % in SI
CLEAR Outcomes: Similar CV Risk Reduction With Bempedoic Acid . . . Bempedoic acid is similar with statin therapy at decreasing the risk of a first major vascular event per every 1 mmol L reduction in LDL-C, according to a post hoc analysis of the CLEAR Outcomes trial, published in JACC